## CRL: Charles River Laboratories International, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($189.67)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Moderate Buy" from Analysts**
- Source: MarketBeat | 20251229T064315 | Somewhat-Bullish | Relevance: 100%
- Charles River Laboratories International, Inc. (NYSE:CRL) has received an average rating of "Moderate Buy" from eighteen analyst firms, with a consensus 12-month average target price of $195.93. Several analysts recently adjusted their price targets, indicating continued interest in the stock. Despite trading near its 52-week high and institutional ownership of nearly 99%, the company reported a negative P/E ratio and net margin, reflecting recent margin pressures.

**2. Allspring Global Investments Holdings LLC Sells 113,185 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251231T084805 | Neutral | Relevance: 100%
- Allspring Global Investments Holdings LLC reduced its stake in Charles River Laboratories International (NYSE:CRL) by 4.9%, selling 113,185 shares. The firm now holds 2,177,941 shares, valued at approximately $371.3 million, making CRL its 21st biggest holding. Other institutional investors have also adjusted their positions, with several increasing their holdings in the medical research company.

**3. Charles River Laboratories International, Inc. $CRL Shares Purchased by Boston Trust Walden Corp**
- Source: MarketBeat | 20251230T100752 | Bullish | Relevance: 100%
- Boston Trust Walden Corp increased its stake in Charles River Laboratories International (NYSE:CRL) by 36.4% in the third quarter, owning 307,242 shares valued at $48.07 million. Several other institutional investors also adjusted their positions in CRL, with hedge funds and institutional investors owning 98.91% of the stock. Analyst ratings for Charles River Laboratories show a "Moderate Buy" consensus with a target price of $195.93.

**4. Charles River Laboratories Stock Tests Investor Patience as Biopharma Recalibrates**
- Source: AD HOC NEWS | 20251230T034113 | Neutral | Relevance: 100%
- Charles River Laboratories (CRL) stock is currently in a complex market phase due to biopharma headwinds, regulatory concerns, and cautiously optimistic future growth prospects. While the company is strategically important in preclinical research and biologics testing, its stock performance has lagged the broader market, prompting investor patience. Wall Street analysts generally rate CRL as "Buy" or "Overweight," seeing the stock as undervalued for its long-term potential, despite near-term uncertainties in biopharma spending and regulatory risks.

**5. Charles River Laboratories International, Inc. $CRL Stake Cut by Norris Perne & French LLP MI**
- Source: MarketBeat | 20251229T122958 | Somewhat-Bullish | Relevance: 100%
- Norris Perne & French LLP MI significantly reduced its stake in Charles River Laboratories International (NYSE:CRL) by 92% in Q3, selling over 110,000 shares. Despite this, other institutional investors have recently increased their positions, and Charles River Laboratories reported strong Q3 earnings, beating analyst estimates with $2.43 EPS and $1 billion in revenue. The company maintains a "Moderate Buy" analyst consensus with a target price around $195.93.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Mizuho | $200 | $174 | +15% |
| 2025-12-15 | Barclays | $215 | $210 | +2% |
| 2025-12-15 | JP Morgan | $190 | $165 | +15% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Mizuho | main | Neutral |
| 2025-12-15 | Barclays | main | Overweight |
| 2025-12-15 | JP Morgan | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.15 indicates undervaluation relative to growth. Forward P/E 18.2x stretched relative to 7% growth. Analyst sentiment positive (3 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.8B |
| Beta | 1.64 |
| 52W Range | $91.86 - $205.00 |
| Short Interest | 5.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.15 |
| Forward P/E | 18.2 |
| Current P/E | 19.5 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.2% to -0.1% (-1.3% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.1pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: -F0L (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.08% (CS: 58) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | -0.06 | Bearish |
| vs SMA20 | 1.021x | Above |
| vs SMA50 | 1.087x | Above |
| vs SMA200 | 1.259x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $199.47
- **Stop Loss:** $189.67 (4.9% risk)
- **Target:** $209.27 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 146
- **Position Value:** $29,122.62
- **Portfolio %:** 29.12%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with mixed signals requiring caution. VIX at 14.95 suggests calm markets, but record repo borrowing and narrowing breadth (51.4%) indicate stress beneath the surface. Positive yield curve (+62bps) and stable economic data support risk assets, but year-end dynamics mask true liquidity conditions.*

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*